Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (681-690 of 934) with videos related to

Pageof 94
Sort By:
Lancet (London, England)|March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialFaiez Zannad, Christopher P Cannon, William C Cushman, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trialClare Arnott, Yuli Huang, Brendon L Neuen, et al.
The American Journal of Cardiology|October 7, 1997
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial InfarctionC P Cannon, P J Sharis, M J Schweiger, et al.
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events TrialM Vardi, B L Cryer, M Cohen, et al.
The American Journal of Cardiology|August 30, 2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)Emmanouil S Brilakis, James A de Lemos, Christopher P Cannon, et al.
Circulation|July 13, 2000
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trialC P Cannon, C H McCabe, R G Wilcox, et al.
JAMA Cardiology|March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) StudyEric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Clinical Cardiology|October 10, 2019
Interleukin-18 in patients with acute coronary syndromesAxel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The New England Journal of Medicine|November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart diseaseChristopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Pageof 94

Showing results (681-690 of 934) with videos related to

Sort By:
Pageof 94
Lancet (London, England)|March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialFaiez Zannad, Christopher P Cannon, William C Cushman, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trialClare Arnott, Yuli Huang, Brendon L Neuen, et al.
The American Journal of Cardiology|October 7, 1997
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial InfarctionC P Cannon, P J Sharis, M J Schweiger, et al.
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events TrialM Vardi, B L Cryer, M Cohen, et al.
The American Journal of Cardiology|August 30, 2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)Emmanouil S Brilakis, James A de Lemos, Christopher P Cannon, et al.
Circulation|July 13, 2000
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trialC P Cannon, C H McCabe, R G Wilcox, et al.
JAMA Cardiology|March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) StudyEric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Clinical Cardiology|October 10, 2019
Interleukin-18 in patients with acute coronary syndromesAxel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The New England Journal of Medicine|November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart diseaseChristopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Pageof 94